Literature DB >> 17362895

Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK,ACh channels in patients with chronic atrial fibrillation.

Niels Voigt1, Adina Friedrich, Manja Bock, Erich Wettwer, Torsten Christ, Michael Knaut, Ruth H Strasser, Ursula Ravens, Dobromir Dobrev.   

Abstract

OBJECTIVE: In chronic atrial fibrillation (cAF) the potassium current IK,ACh develops agonist-independent constitutive activity. We hypothesized that abnormal phosphorylation-dependent regulation underlies the constitutive IK,ACh activity.
METHODS: We used voltage-clamp technique and biochemical assays to study IK,ACh regulation in atrial appendages from 61 sinus rhythm (SR), 11 paroxysmal AF (pAF), and 33 cAF patients.
RESULTS: Compared to SR basal current was higher in cAF only, whereas the muscarinic receptor (2 micromol/L carbachol)-activated IK,ACh was smaller in pAF and cAF. In pAF the selective IK,ACh blocker tertiapin abolished the muscarinic receptor-activated IK,ACh but excluded agonist-independent constitutive IK,ACh activity. Blockade of type-2A phosphatase and the subsequent shift to increased muscarinic receptor phosphorylation (and inactivation) reduced muscarinic receptor-activated IK,ACh in SR but not in cAF, pointing to an impaired function of G-protein-coupled receptor kinase. Using subtype-selective kinase inhibitors we found that in SR the muscarinic receptor-activated IK,ACh requires phosphorylation by protein kinase G (PKG), protein kinase C (PKC), and calmodulin-dependent protein kinase II (CaMKII), but not by protein kinase A (PKA). In cAF, constitutive IK,ACh activity results from abnormal channel phosphorylation by PKC but not by PKG or CaMKII, whereas the additional muscarinic receptor-mediated IK,ACh activation occurs apparently without involvement of these kinases. In cAF, the higher protein level of PKCepsilon but not PKCalpha, PKCbeta1 or PKCdelta is likely to contribute to the constitutive IK,ACh activity.
CONCLUSIONS: The occurrence of constitutive IK,ACh activity in cAF results from abnormal PKC function, whereas the muscarinic receptor-mediated IK,ACh activation does not require the contribution of PKG, PKC or CaMKII. Selective drug targeting of constitutively active IK,ACh channels may be suitable to reduce the ability of AF to become sustained.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17362895     DOI: 10.1016/j.cardiores.2007.02.009

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  37 in total

1.  Isoenzyme-specific regulation of cardiac Kv1.5/Kvβ1.2 ion channel complex by protein kinase C: central role of PKCβII.

Authors:  Fathima Fischer; Nadine Vonderlin; Claudia Seyler; Edgar Zitron; Sevil Korkmaz; Gábor Szabó; Dierk Thomas; Hugo A Katus; Eberhard P Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-02-28       Impact factor: 3.000

Review 2.  Report on the Ion Channel Symposium : Organized by the German Cardiac Society Working Group on Cellular Electrophysiology (AG 18).

Authors:  Niels Voigt; Fleur Mason; Dierk Thomas
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-01-08

Review 3.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

Review 4.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 5.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

Review 6.  Serine/Threonine Phosphatases in Atrial Fibrillation.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Xander H T Wehrens; Dobromir Dobrev
Journal:  J Mol Cell Cardiol       Date:  2017-01-07       Impact factor: 5.000

7.  How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  J Atr Fibrillation       Date:  2008

8.  Novel pharmacological approaches for antiarrhythmic therapy.

Authors:  Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-15       Impact factor: 3.000

9.  Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation.

Authors:  Niels Voigt; Nadiia Rozmaritsa; Anne Trausch; Thomasz Zimniak; Torsten Christ; Erich Wettwer; Klaus Matschke; Dobromir Dobrev; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-17       Impact factor: 3.000

10.  Cellular bases for human atrial fibrillation.

Authors:  Antony J Workman; Kathleen A Kane; Andrew C Rankin
Journal:  Heart Rhythm       Date:  2008-01-17       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.